L&G Pharma Breakthrough UCITS ETF USD Acc
- ISIN
- IE00BF0H7608
- Provider
- LGIM Managers (Europe) Ltd
- Close Price
- CHF 12.11 *
- Lipper Rating
- ESG Score
- Characteristics
- SustainableETF
* Data as of 11 September 2026
Performance
Loading...
| Total | p.a. | |
|---|---|---|
| YTD | +12.02% | — |
| 1 Year | +20.78% | +20.78% |
| 3 Years | +26.12% | +8.04% |
| 5 Years | +0.89% | +0.18% |
Past performance is not a reliable indicator of future results. The value of an investment and the income from it can fall as well as rise.
Key Facts
| Asset Class | Equity |
| Holdings Classification | Equity Global Mid-Cap Growth |
| Geographical Focus | Global |
| Fund Size | CHF 19,803,678 |
| Total Expense Ratio | 0.49% |
| Currency | CHF |
| Domicile | IE |
| Managementstyle | Passive |
| SFDR Article | Article 9 |
Available in
Liechtenstein Life InvestLiechtenstein Life PensionLiechtenstein Life WealthProsperity PlusVWL-Förderkonzept für Bundeswehrangehörigebest value rentvalue invest VWLvalue rent business UK
Country Exposure
United States
63.2%
Japan
8.1%
Switzerland
5.5%
Netherlands
5.0%
Ireland
3.2%
Other
15.0%
Description
The L&G Pharma Breakthrough UCITS ETF (the “fund”) is a passively managed exchange traded fund (“ETF”) which aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “index”), after deducting all ongoing and other costs associated with operating the fund. ...